Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Improved quadruplex real-time PCR assay for the diagnosis of diphtheria.

Badell E, Guillot S, Tulliez M, Pascal M, Panunzi LG, Rose S, Litt D, Fry NK, Brisse S.

J Med Microbiol. 2019 Oct;68(10):1455-1465. doi: 10.1099/jmm.0.001070. Epub 2019 Sep 3.

PMID:
31478826
2.

Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone.

Partouche N, Conejero C, Barathon Q, Moroch J, Tulliez M, Cordonnier C, Giraudier S.

Hematol Oncol. 2018 Feb;36(1):336-339. doi: 10.1002/hon.2431. Epub 2017 May 29.

PMID:
28556926
3.

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

PMID:
28095277
4.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX; France Intergroupe des Leucémies Myéloïdes Chroniques.

Blood. 2017 Feb 16;129(7):846-854. doi: 10.1182/blood-2016-09-742205. Epub 2016 Dec 8.

PMID:
27932374
5.

Impact of ELN recommendations in the management of first-line treated chronic myeloid leukaemia patients: a French cross-sectional study.

Etienne G, Huguet F, Guerci-Bresler A, Nicolini FE, Maloisel F, Coiteux V, Dauriac C, Carpentier N, Bourdeix I, Tulliez M, Cony-Makhoul P.

Br J Haematol. 2016 Jul;174(1):71-80. doi: 10.1111/bjh.14022. Epub 2016 Apr 7.

PMID:
27060881
6.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

Rea D, Ame S, Charbonnier A, Coiteux V, Cony-Makhoul P, Escoffre-Barbe M, Etienne G, Gardembas M, Guerci-Bresler A, Legros L, Nicolini F, Tulliez M, Hermet E, Huguet F, Johnson-Ansah H, Lapusan S, Quittet P, Rousselot P, Mahon FX, Messas E.

Bull Cancer. 2016 Feb;103(2):180-9. doi: 10.1016/j.bulcan.2015.11.008. Epub 2016 Jan 11. French.

PMID:
26790711
7.

Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.

Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, Villeval JL, Raslova H, Kralovics R, Constantinescu SN, Plo I, Vainchenker W.

Blood. 2016 Mar 10;127(10):1317-24. doi: 10.1182/blood-2015-11-679571. Epub 2015 Nov 25.

PMID:
26608331
8.

Reply to J. Richter et al.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. No abstract available.

PMID:
25071119
9.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX.

J Clin Oncol. 2014 Feb 10;32(5):424-30. doi: 10.1200/JCO.2012.48.5797. Epub 2013 Dec 9.

PMID:
24323036
10.

Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.

Roux C, Nicolini FE, Rea D, Niault M, Mollica L, Berger F, Chassagne-Clément C, Tigaud I, Tulliez M, Giraudier S, Turhan A, Rousselot P, Legros L.

Blood. 2013 Oct 24;122(17):3082-4. doi: 10.1182/blood-2013-07-513879. No abstract available.

PMID:
24159167
11.

Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.

Delgado L, Giraudier S, Ortonne N, Zehou O, Cordonnier C, Hulin A, Chosidow O, Tulliez M, Valeyrie-Allanore L.

J Am Acad Dermatol. 2013 Nov;69(5):839-840. doi: 10.1016/j.jaad.2013.07.025. No abstract available.

PMID:
24124828
12.

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.

Legros L, Rousselot P, Giraudier S, Tulliez M, Huguet F, Nicolini FE, Mahon FX.

Blood. 2012 Aug 30;120(9):1959-60. doi: 10.1182/blood-2012-02-408229. No abstract available.

13.

First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia.

Rea D, Etienne G, Nicolini F, Cony-Makhoul P, Johnson-Ansah H, Legros L, Huguet F, Tulliez M, Gardembas M, Bouabdallah K, Rousselot P, Cayuela JM, Guilhot F, Mahon FX.

Leukemia. 2012 Oct;26(10):2254-9. doi: 10.1038/leu.2012.92. Epub 2012 Mar 30.

PMID:
22460758
14.

The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia.

Green AS, Grabar S, Tulliez M, Park S, Al-Nawakil C, Chapuis N, Jacque N, Willems L, Azar N, Ifrah N, Dreyfus F, Lacombe C, Mayeux P, Bouscary D, Tamburini J.

Br J Haematol. 2012 Feb;156(4):547-50. doi: 10.1111/j.1365-2141.2011.08891.x. Epub 2011 Oct 14. No abstract available.

PMID:
21995271
15.

Cartridge-based automated BCR-ABL1 mRNA quantification: solving the issues of standardization, at what cost?

Cayuela JM, Macintyre E, Darlington M, Abdelali RB, Fund X, Villarese P, Tulliez M, Raffoux E, Sigaux F, Réa D, Seror V.

Haematologica. 2011 May;96(5):664-71. doi: 10.3324/haematol.2010.034389. Epub 2011 Feb 17.

16.

Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis.

Evrard S, Bluteau O, Tulliez M, Rameau P, Gonin P, Zetterberg E, Palmblad J, Bonnefoy A, Villeval JL, Vainchenker W, Giraudier S, Wagner-Ballon O.

Blood. 2011 Jan 6;117(1):246-9. doi: 10.1182/blood-2010-07-294447. Epub 2010 Oct 13.

PMID:
20944070
17.

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M.

Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3.

PMID:
20605207
18.

[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)].

Etienne G, Milpied B, Réa D, Rigal-Huguet F, Tulliez M, Nicolini FE; French Intergroup of CML (Fi-LMC group).

Bull Cancer. 2010 Aug;97(8):997-1009. doi: 10.1684/bdc.2010.1136. French.

19.

Toxicological evaluation of RGTA OTR4120, a heparan sulfate mimetic.

Charef S, Tulliez M, Esmilaire L, Courty J, Papy-Garcia D.

Food Chem Toxicol. 2010 Jul;48(7):1965-8. doi: 10.1016/j.fct.2010.04.045. Epub 2010 May 7.

PMID:
20452387
20.

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study.

Michallet M, Tulliez M, Corm S, Gardembas M, Huguet F, Oukessou A, Bregman B, Vekhoff A, Ghomari K, Cambier N, Guerci-Bresler A.

Curr Med Res Opin. 2010 Feb;26(2):307-17. doi: 10.1185/03007990903479299.

PMID:
19961284
21.

[Eosinophilic pleural effusion associated to Churg and Strauss syndrome].

Natali D, Tulliez M, Burgel PR, Mouthon L, Dusser D, Montani D.

Rev Pneumol Clin. 2008 Oct;64(5):229-33. doi: 10.1016/j.pneumo.2007.12.001. Epub 2008 Oct 23. French.

PMID:
18995151
22.

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.

James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, Lippert E, Mahon FX, Pasquet JM, Etienne G, Delhommeau F, Giraudier S, Vainchenker W, de Verneuil H.

Blood. 2008 Sep 15;112(6):2429-38. doi: 10.1182/blood-2008-02-137877. Epub 2008 Jul 8.

PMID:
18612101
23.

The JAK2(V617F) mutation may be present several years before the occurrence of overt myeloproliferative disorders.

Bellanné-Chantelot C, Jego P, Lionne-Huyghe P, Tulliez M, Najman A; French group on myeloproliferative disorders.

Leukemia. 2008 Feb;22(2):450-1. Epub 2007 Sep 13. No abstract available.

PMID:
17851561
24.

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.

Nicolini FE, Hayette S, Corm S, Bachy E, Bories D, Tulliez M, Guilhot F, Legros L, Maloisel F, Kiladjian JJ, Mahon FX, Lê QH, Michallet M, Roche-Lestienne C, Preudhomme C.

Haematologica. 2007 Sep;92(9):1238-41.

25.

The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient.

Bouvresse S, Marcelin AG, Franck N, Regnier S, Damond F, Tulliez M, Dupin N.

AIDS. 2007 Jul 11;21(11):1492-4. No abstract available. Erratum in: AIDS. 2007 Oct 18;21(16):2257. Sophie, Bouvresse [corrected to Bouvresse, Sophie]; Anne-Geneviève, Marcelin [corrected to Marcelin, Anne-Geneviève]; Nathalie, Franck [corrected to Franck, Nathalie]; Stéphanie, Regnier [corrected to Regnier, Stéphanie]; Florence, Damond [corrected to.

PMID:
17589201
26.

Pericyte coverage of abnormal blood vessels in myelofibrotic bone marrows.

Zetterberg E, Vannucchi AM, Migliaccio AR, Vainchenker W, Tulliez M, Dickie R, Hasselbalch H, Rogers R, Palmblad J.

Haematologica. 2007 May;92(5):597-604.

27.

Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.

Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligné R, Lacout C, Auradé F, Villeval JL, Gonin P, Vainchenker W, Giraudier S.

Blood. 2007 Jul 1;110(1):345-53. Epub 2007 Mar 20.

PMID:
17374740
28.

Adenoviral-mediated TGF-beta1 inhibition in a mouse model of myelofibrosis inhibit bone marrow fibrosis development.

Gastinne T, Vigant F, Lavenu-Bombled C, Wagner-Ballon O, Tulliez M, Chagraoui H, Villeval JL, Lacout C, Perricaudet M, Vainchenker W, Benihoud K, Giraudier S.

Exp Hematol. 2007 Jan;35(1):64-74.

PMID:
17198875
29.

Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin.

Wagner-Ballon O, Chagraoui H, Prina E, Tulliez M, Milon G, Raslova H, Villeval JL, Vainchenker W, Giraudier S.

J Immunol. 2006 Jun 1;176(11):6425-33.

30.

Life-threatening hemophagocytic syndrome related to mycobacterium tuberculosis.

Claessens YE, Pene F, Tulliez M, Cariou A, Chiche JD.

Eur J Emerg Med. 2006 Jun;13(3):172-4.

PMID:
16679883
31.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60. Epub 2006 May 2.

PMID:
16670266
32.

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).

Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C.

Leukemia. 2006 Jun;20(6):1061-6.

PMID:
16642048
33.

A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.

Bouscary D, Legros L, Tulliez M, Dubois S, Mahe B, Beyne-Rauzy O, Quarre MC, Vassilief D, Varet B, Aouba A, Gardembas M, Giraudier S, Guerci A, Rousselot P, Gaillard F, Moreau A, Rousselet MC, Ifrah N, Fenaux P, Dreyfus F; Groupe Français des Myélodysplasies (GFM).

Br J Haematol. 2005 Dec;131(5):609-18.

PMID:
16351636
34.

Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.

James C, Delhommeau F, Marzac C, Teyssandier I, Couédic JP, Giraudier S, Roy L, Saulnier P, Lacroix L, Maury S, Tulliez M, Vainchenker W, Ugo V, Casadevall N.

Leukemia. 2006 Feb;20(2):350-3. No abstract available.

PMID:
16341032
35.

[Epstein-Barr virus-associated cutaneous plasmacytoma post-solid organ transplantation].

Buffet M, Dupin N, Carlotti A, De Muret A, Tulliez M, Calmus Y, Sirinelli A, Bouscary D, Escande JP, Vaillant L; Groupe Français D'Etude Des Lymphomes Cutanés.

Ann Dermatol Venereol. 2004 Dec;131(12):1085-91. Review. French.

PMID:
15692444
36.

Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas.

Kelaidi C, Rollot F, Park S, Tulliez M, Christoforov B, Calmus Y, Podevin P, Bouscary D, Sogni P, Blanche P, Dreyfus F.

Leukemia. 2004 Oct;18(10):1711-6.

PMID:
15284859
37.

Pseudouveitis: a clue to the diagnosis of primary central nervous system lymphoma in immunocompetent patients.

Park S, Abad S, Tulliez M, Monnet D, Merlat A, Gyan E, Bouscary D, Dreyfus F, Grimaldi D, Dhote R, Rollot F, Kelaïdi C, Nazal EM, Brézin AP, Blanche P.

Medicine (Baltimore). 2004 Jul;83(4):223-32.

38.

Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients.

Marcelin AG, Roque-Afonso AM, Hurtova M, Dupin N, Tulliez M, Sebagh M, Arkoub ZA, Guettier C, Samuel D, Calvez V, Dussaix E.

Liver Transpl. 2004 Feb;10(2):295-300.

39.

Delayed viral replication and CD4(+) T cell depletion in the rectosigmoid mucosa of macaques during primary rectal SIV infection.

Couëdel-Courteille A, Prétet JL, Barget N, Jacques S, Petitprez K, Tulliez M, Guillet JG, Venet A, Butor C.

Virology. 2003 Nov 25;316(2):290-301.

40.

Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.

Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F; CML French Group.

Blood. 2003 Dec 15;102(13):4298-305. Epub 2003 Aug 21.

PMID:
12933584
41.

Spontaneous STAT5 activation induces growth factor independence in idiopathic myelofibrosis: possible relationship with FKBP51 overexpression.

Komura E, Chagraoui H, Mansat de Mas V, Blanchet B, de Sepulveda P, Larbret F, Larghero J, Tulliez M, Debili N, Vainchenker W, Giraudier S.

Exp Hematol. 2003 Jul;31(7):622-30.

PMID:
12842707
42.

Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.

Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group.

Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. Review.

PMID:
12783382
43.

Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.

Rousselot P, Larghero J, Raffoux E, Calvo F, Tulliez M, Giraudier S, Rybojad M.

Br J Haematol. 2003 Mar;120(6):1091-2. No abstract available.

PMID:
12648085
44.

Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.

Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, Tulliez M, Giraudier S.

J Am Acad Dermatol. 2003 Feb;48(2):201-6.

PMID:
12582389
45.

Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO.

Chagraoui H, Tulliez M, Smayra T, Komura E, Giraudier S, Yun T, Lassau N, Vainchenker W, Wendling F.

Blood. 2003 Apr 15;101(8):2983-9. Epub 2002 Dec 27.

PMID:
12506018
46.

Congenital dyserythropoietic anemia type I is caused by mutations in codanin-1.

Dgany O, Avidan N, Delaunay J, Krasnov T, Shalmon L, Shalev H, Eidelitz-Markus T, Kapelushnik J, Cattan D, Pariente A, Tulliez M, Crétien A, Schischmanoff PO, Iolascon A, Fibach E, Koren A, Rössler J, Le Merrer M, Yaniv I, Zaizov R, Ben-Asher E, Olender T, Lancet D, Beckmann JS, Tamary H.

Am J Hum Genet. 2002 Dec;71(6):1467-74. Epub 2002 Nov 14.

47.

Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.

Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F.

Blood. 2002 Nov 15;100(10):3495-503. Epub 2002 Jul 5.

PMID:
12393681
48.

Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.

Kelaïdi C, Tulliez M, Lecoq-Lafon C, Pham XV, Kahan A, Dreyfus F, Bouscary D.

Leukemia. 2002 Oct;16(10):2173-4. No abstract available.

49.

Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors.

Giraudier S, Chagraoui H, Komura E, Barnache S, Blanchet B, LeCouedic JP, Smith DF, Larbret F, Taksin AL, Moreau-Gachelin F, Casadevall N, Tulliez M, Hulin A, Debili N, Vainchenker W.

Blood. 2002 Oct 15;100(8):2932-40.

PMID:
12351405
50.

Inflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequences.

Kamate C, Baloul S, Grootenboer S, Pessis E, Chevrot A, Tulliez M, Marchiol C, Viguier M, Fradelizi D.

Int J Cancer. 2002 Aug 10;100(5):571-9.

Supplemental Content

Loading ...
Support Center